EDAP logo

EDAP TMS S.A. Stock Price

NasdaqGM:EDAP Community·US$130.8m Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

EDAP Share Price Performance

US$3.42
1.98 (137.50%)
US$6.83
Fair Value
US$3.42
1.98 (137.50%)
50.0% undervalued intrinsic discount
US$6.83
Fair Value
Price US$3.42
AnalystConsensusTarget US$6.83
LuckyII US$10.74
AnalystLowTarget US$2.50

EDAP Community Narratives

AnalystConsensusTarget·
Fair Value US$6.83 50.0% undervalued intrinsic discount

Global HIFU Adoption Will Open New Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
LuckyII·
Fair Value US$10.74 68.2% undervalued intrinsic discount

A surgeon's dream

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value US$2.5 36.8% overvalued intrinsic discount

Tariffs And Delays Will Hinder Progress Though Trials Offer Hope

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$10.74
68.2% undervalued intrinsic discount
Fair Value
Profit Margin
13.76%
Future PE
24x
Price in 2031
US$13.72

Trending Discussion

Updated Narratives

EDAP logo

A surgeon's dream

Fair Value: US$10.74 68.2% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
EDAP logo

EDAP: Revised Outlook Will Rely On 2026 Revenue Guidance Execution

Fair Value: US$10 65.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
EDAP logo

EDAP: Longer Term Revenue Outlook Will Support Future Upside

Fair Value: US$6.83 50.0% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Mediocre balance sheet and slightly overvalued.

2 Risks
1 Reward

EDAP TMS S.A. Key Details

US$70.5m

Revenue

US$40.5m

Cost of Revenue

US$30.0m

Gross Profit

US$59.2m

Other Expenses

-US$29.2m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 07, 2026
-0.78
42.54%
-41.47%
124.0%
View Full Analysis

About EDAP

Founded
1979
Employees
310
CEO
Ryan Rhodes
WebsiteView website
focalone.com

EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.

Recent EDAP News & Updates

Recent updates

No updates